Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKGSRZ)

Drug Name

C-176 Drug Info

Synonyms

314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; STING inhibitor C-176; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1

Indication

Disease Entry	ICD 11	Status	REF
Aicardi-Goutieres syndrome	5C55.2	Investigative	[1]

Cross-matching ID

PubChem CID: 1103958
TTD Drug ID: DMKGSRZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Stimulator of interferon genes protein (TMEM173)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ADU-S100	DM8HBUI	Head and neck cancer	2D42	Phase 2	[3]
ADU- S100	DMM6B2Y	Head and neck cancer	2D42	Phase 2	[4]
MK-1454	DMEDITW	Squamous head and neck cell carcinom	2D60.0	Phase 2	[5]
IMSA101	DM43ICH	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
BMS-986301	DMM3DBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
MK-2118	DMKNH8B	Lymphoma	2A80-2A86	Phase 1	[8]
SB 11285	DMZ9YWG	Head-neck squamous cell carcinoma	2D60.0	Phase 1	[9]
E7766	DM8TU5R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
GSK3745417	DMRYNJD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
TAK-676	DMCKF5J	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stimulator of interferon genes protein (TMEM173)	TTT402Y	STING_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2019 Nov;18(11):845-867.
2	Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
5	National Cancer Institute Drug Dictionary (drug name MK1454).
6	Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
7	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
8	National Cancer Institute Drug Dictionary (drug name ML2118).
9	Clinical pipeline report, company report or official report of F-star Therapeutics.
10	E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
11	National Cancer Institute Drug Dictionary (drug name GSK3745417).
12	National Cancer Institute Drug Dictionary (drug name TAK676).